Lab tests can reveal how patients respond to Gleevec

November 25, 2003

PORTLAND, Ore. -- An international team of researchers has concluded that lab testing can reveal ahead of time just how well patients with certain gastrointestinal cancers will respond to therapy with the drug Gleevec, according to study results published in the December 1, 2003, Journal of Clinical Oncology.

Patients with a favorable lab result had an 84 percent chance of a partial remission in response to Gleevec, while none of the patients with an unfavorable lab result had a partial remission.

"These results demonstrate that the most important predictor of tumor shrinkage during Gleevec therapy is not patient age, overall health status, or tumor size, but rather the specific type of mutation causing the tumor," said Michael Heinrich, M.D., member of the Oregon Health & Science University Cancer Institute, associate professor of medicine (hematology and medical oncology) in the OHSU School of Medicine and the Portland VA Medical Center, and co-principal investigator of the study.

Gastrointestinal stromal tumors (GISTs), which occur in the stomach and intestines, are diagnosed in up to 10,000 Americans annually. Surgery is the treatment of choice for localized tumors, but in many patients the tumor recurs and spreads elsewhere, particularly to the liver. Up until two years ago, at this metastatic stage, the disease was invariably fatal because chemotherapy, radiation and surgery are ineffective in advanced cases. More recently, however, physicians have shown that metastatic GISTs are responsive to Gleevec.

Gleevec, technically known as a tyrosine kinase inhibitor, was first introduced for the treatment of chronic myelogenous leukemia (CML), the growth of which is driven by a mutant tyrosine kinase enzyme called BCR-ABL. Gleevec is a potent inhibitor of the BCR-ABL enzyme, effectively shutting down the growth of leukemia cells with relatively minor side effects.

Gleevec also inhibits a related tyrosine kinase called KIT. The presence of mutant KIT protein in GISTs led researchers to suspect that Gleevec would be an effective treatment for this cancer.

"The majority of GI stromal tumors have a mutant form of KIT that acts like a gas pedal stuck to the floor, providing a constant stimulus for GIST cells to grow," Heinrich said.

A fast-tracked clinical trial proved this hypothesis, and the drug was approved by the FDA in 2002 for patients with advanced GIST. The clinical trial was performed at the OHSU Cancer Institute, Dana-Farber Cancer Institute, Fox Chase Cancer Center and the University Hospital of Helsinki, Finland.

"In many patients, treatment with Gleevec inhibited the KIT activity that was driving tumor growth," Heinrich said.

While the majority of GIST patients treated in the Gleevec trial benefited from the drug, a subset did not respond well, and the latest research was designed to reveal why. The researchers analyzed DNA samples of GIST tumors from 127 patients enrolled in the trial to determine whether a KIT tyrosine kinase mutation was present and whether the specific type of mutation had an impact on drug response.

The results revealed three distinct subsets of GIST. Those with "exon 11" mutations of KIT responded well to Gleevec; 84 percent of patients with such tumors had a partial remission (greater than 50 percent shrinkage of their tumors), and half of the members of this group are still benefiting from the drug after 22 months. GISTs that lacked a KIT mutation, however, did not respond well to Gleevec. None of the patients in this group had a partial remission, and half of the patients failed treatment within the first 90 days. GIST with an "exon 9" mutation of KIT responded in an intermediate fashion in the trial, with half of the patients failing treatment after 187 days.

"KIT mutation status not only predicted the likelihood of Gleevec response, it was also the most important predictor of duration of response and overall patient survival in the trial," Heinrich said.

Further studies by Heinrich and his colleagues also revealed a new wrinkle in the GIST story. Among the tumors that lacked a KIT mutation, some had a mutation in a different (but closely related) tyrosine kinase called PDGFRA. While mutations in this kinase were found in only 4.7 percent of GIST cases in the Gleevec clinical trial, the drug was effective against some of these PDGFRA mutations.

"We are in the process of studying the PDGFRA mutations, but so far preliminary data suggest that there are parallels with KIT @ that is, if a PDGFRA mutation is present, then Gleevec response can be predicted by the exact type of mutation," Heinrich said.

The study results suggest that clinical testing for specific mutation type may help clinicians treat patients with GIST. KIT mutational testing is now available at OHSU and testing for the newly identified PDGFRA mutations will be available soon.

"Mutational testing can be helpful in confirming the diagnosis of GIST and in defining the prognosis for patients who need Gleevec therapy," said Christopher Corless, M.D., associate professor of pathology in the OHSU School of Medicine and co-investigator in the GIST research.

Also study co-investigators are Brian Druker, M.D., JELD-WEN Chair of Leukemia Research at the OHSU Cancer Institute and an investigator of the Howard Hughes Medical Institute and Charles Blanke, M.D., director of the gastrointestinal malignancy program at the OHSU Cancer Institute, associate professor of medicine (hematology and medical oncology) in the OHSU School of Medicine and the Portland VA Medical Center.

"As Gleevec is used more and more in combination with surgery, we believe that testing for mutations in GIST will be important in deciding whether Gleevec therapy should be used before and/or after surgery for GIST," Heinrich said.
-end-
This study was funded in part by the U.S. Department of Veterans Affairs.

To access all OHSU news releases, visit http://www.ohsu.edu.
Contact: Rachel MacKnight, 503-494-8231 or macknigh@ohsu.edu.

Oregon Health & Science University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.